Puretech Health Plc · LSE:PRTC
Puretech Health — Investor Presentation (March 2026)
37 slides from Puretech Health's investor presentation, March 2026
Slide 1: Deupirfenidone: Supplemental Slides
DEUPIRFENIDONE: A potential new standard of care for idiopathic pulmonary fibrosis (IPF) and other rare lung diseases Supplemental Slides
Slide 2: Table of Contents
Table of Contents Executive Summary IPF: Rare Lung Disease with High Unmet Need Phase 2b ELEVATE IPF Trial Phase 3 SURPASS-IPF Trial Design Commercial Opportunity Appendix Historical IPF Trial Failures and PureTech Differentiation 2
Slide 3: Executive Summary
bad : BURETECH = o GIVING LIFE TO SCIENCE”
Slide 4: Deupirfenidone: A Potential New Standard-of-care for IPF and other PPFs
Deupirfenidone: A Potential New Standard-of-care for IPF and other PPFs • Debilitating, fatal disease; current SOC agents cannot High Patient Need be taken in high doses due to poor tolerability, resulting in suboptimal efficacy • Builds Opportunity established on to to expand human efficacy multipl
Slide 5: Deupirfenidone is a Novel Compound
Deupirfenidone is a Novel Compound STRUCTURE OVERVIEW DEUTERIUM SUBSTITUTION ▶ Leverages clinically validated pirfenidone1 New chemical entity with potential for improved efficacy without with strategically sacrificing tolerability placed deuterium ▶ Composition of matter patent exclusivity up (heav
Slide 6: Milestones Achieved and Catalysts
Milestones Achieved and Catalysts December 2024 Successful completion of Phase 2b trial Additional data from Phase 2b presented at ATS Preliminary 52-week OLE data demonstrated durable treatment effect May 2025 101 patients received at least 52 weeks of treatment to date1 Successful End of P
Slide 7: IPF: Rare Lung Disease with High Unmet Need
Idiopathic Pulmonary Fibrosis (IPF): Rare Lung Disease with High Unmet Need 7
Slide 8: Idiopathic Pulmonary Fibrosis (IPF) Overview
Idiopathic Pulmonary Fibrosis (IPF) Overview IPF is a progressive and fatal disease with a significantly unaddressed patient population >232,000 ~2-5 years IPF patients in the US & EU51 Involves scarring of the lungs, leading Life expectancy of IPF to shortness of breath and loss of lung without tre
Slide 9: Efficacy is the Key Prescribing Focus for Pulmonologists
Efficacy is the Key Prescribing Focus for Pulmonologists The majority of respondents prioritize efficacy (over safety/tolerability) in trying to optimize therapy for IPF patients, regardless of practice setting (2025 analysis) Recognizing the Tradeoffs Between Efficacy and Safety/Tolerability, If I
Slide 10: Improved Efficacy is Key Treatment Priority for People Living with IPF
Improved Efficacy is Key Treatment Priority for People Living with IPF The majority of survey participants indicated they would prefer a treatment with improved efficacy over one with improved safety Patient Preferences for New IPF Therapies1 69% “Efficacy is far more important to me than anything e
Slide 11: Stabilizing Lung Function is the Ultimate Treatment Goal in IPF
Stabilizing Lung Function is the Ultimate Treatment Goal in IPF Pulmonologists and patients seek improved efficacy without sacrificing tolerability1 Change in Forced Vital Capacity (FVC) Over 52 Weeks 100 Change in Forced Vital Capacity (FVC) from Baseline 80 Natural lung function decline (~-50 mL)2
Slide 12: Phase 2b ELEVATE IPF Trial
bad : BURETECH = o GIVING LIFE TO SCIENCE”
Slide 13: ELEVATE Trial Demonstrated Unprecedented Efficacy for Deupirfenidone 825 mg TID
ELEVATE Trial Demonstrated Unprecedented Efficacy for Deupirfenidone 825 mg TID POTENTIAL FOR LUNG ENHANCED EFFICACY DURABLE EFFICACY SUPPORTING FUNCTION VERSUS CURRENT RESPONSE OUT TO 52 PHARMACOKINETIC (PK) STABILIZATION STANDARD OF CARE WEEKS DATA Deupirfenidone 825 mg TID Deupirfenidone 825 mg T
Slide 14: ELEVATE: Global, Phase 2b, Multicenter, Randomized, Double-blind Clinical Trial
ELEVATE: Global, Phase 2b, Multicenter, Randomized, Double- blind Clinical Trial 26 Weeks of Double-Blind Study Treatment Open Label Extension Screening (Part A) (Part B) (≤ 28 days) V2 V3 V4 V5 V6 V7 V8 D1 W4 W8 W12 W16 W20 W26 Deupirfenidone Deupirfenidone 550 mg TID Deupirfenidone 550 mg TID 550
Slide 15: ELEVATE: 257 Patients Recruited from 87 Sites in 14 Countries
ELEVATE: Global, Phase 2b, Multicenter, Randomized, Double- blind Clinical Trial 257 patients were recruited from 87 sites across 14 countries KEY DEMOGRAPHIC STATISTICS Romania Georgia South Korea ▶ Median age: 72 years, 6 Patients 20 Patients 38 Patients 13.6% ≥ 80 years United States ▶ 71.2% Male
Slide 16: Overview of ELEVATE Statistical Approach
Overview of ELEVATE Statistical Approach Commonly used Bayesian1 and frequentist analyses were applied ▶ We obtained FVC data per patient over time, BAYESIAN STATISTICS commonly referred to as observed data Used for Primary and Key Secondary Endpoints ▶ Observed data doesn’t account for missing data
Slide 17: ELEVATE Achieved Primary and Key Secondary Endpoints
ELEVATE Achieved Primary and Key Secondary Endpoints Posterior Mean (SE) Change from Baseline in FVC (mL) over 26 Weeks Posterior Mean (SE) Change from Baseline in FVCpp over 26 Weeks Change from Baseline in Forced Vital Capacity (FVC) over 26 Change from Baseline in Forced Vital Capacity % Predicte
Slide 18: Deupirfenidone Demonstrated Potential to Serve as a New Standard-of-Care Treatment for IPF
Deupirfenidone Demonstrated Potential to Serve as a New Standard-of-Care Treatment for IPF Adjusted Mean (SE) Change from Baseline in FVC (mL) over 26 Weeks Change from Baseline in Forced Vital Capacity (FVC) over 26 Change from Baseline in Forced Vital Capacity % Predicted Adjusted Mean (SE) Change
Slide 19: Deupirfenidone 825 mg TID Stabilized Lung Function; Rate of Decline Similar to Healthy Older Adults
Deupirfenidone 825 mg TID Stabilized Lung Function; Rate of Decline Similar to Healthy Older Adults Change from Baseline in Forced Vital Capacity (FVC) Over 26 Weeks (mL) 0 -20 -21.5 mL -15 to -25 mL -40 -60 FVC decline for deupirfenidone 825 mg TID at 26 weeks -80 in ELEVATE approached the level of
Slide 20: Deupirfenidone Demonstrated a Clear Dose-dependent Effect
Deupirfenidone Demonstrated a Clear Dose-dependent Effect Change from baseline in FVC and FVCpp (Mixed Model Repeated Measure with Random Slope Regression) Adjusted Mean (SE) Change from Baseline in Forced Vital Adjusted Mean (SE) Change from Baseline in Forced Vital Capacity Capacity (FVC) Over Tim
Slide 21: Versus Placebo, Deupirfenidone 825 mg TID Had ~50% Greater Effect Size than Pirfenidone
Versus Placebo, Deupirfenidone 825 mg TID Had ~50% Greater Effect Size than Pirfenidone in ELEVATE Trial Treatment Effect from Change in Forced Vital Capacity (FVC) and Percent Predicted Forced Vital Capacity (FVCpp) Across Arms 90% 87.5% 80.9% 80% 70% 57.4% 60% 54.1% 50% 47.2% 40% 28.3% 30% 20% 10%
Slide 22: PK Analysis Showed Deupirfenidone 825 mg TID Has ~50% Greater Exposure than Pirfenidone
PK Analysis From ELEVATE Showed That Deupirfenidone 825 mg TID Has ~50% Greater Exposure than Pirfenidone Analysis of Estimated AUC for Deupirfenidone ELEVATE PK Summary and Pirfenidone Deupirfenidone 550 mg Deupirfenidone 825 mg ▶ Deupirfenidone 825 mg TID had TID vs. Pirfenidone TID vs. Pirfenidon
Slide 23: Deupirfenidone Had Favorable Tolerability in ELEVATE Trial
Deupirfenidone Had Favorable Tolerability in ELEVATE Trial Summary of Most Common (≥5% in Any Treatment Group) TEAEs by SOC, PT, and Treatment Group (Safety Set) Placebo Pirfenidone Deupirfenidone Deupirfenidone TID 801 mg TID 550 mg TID 825 mg TID SOC/PT (N=65) (N=63) (N=65) (N=64) n (%) n (%) n (%
Slide 24: Favorable Tolerability Profile Allows for Higher Drug Exposure and Greater Efficacy
Deupirfenidone’s Favorable Tolerability Profile Allows for Higher Drug Exposure and Greater Efficacy Favorable Higher Deuteration PK Greater Tolerability Dose & Higher Differentiation Efficacy Profile Exposure 24
Slide 25: >90% of Patients Opted to Enroll in the Ongoing Open-label Extension
>90% of Patients Opted to Enroll in the Ongoing Open-label Extension 26 Weeks of Double-Blind Study Treatment Open Label Extension Screening (Part A) (Part B) (≤ 28 days) V2 V3 V4 V5 V6 V7 V8 D1 W4 W8 W12 W16 W20 W26 Deupirfenidone Deupirfenidone 550 mg TID Deupirfenidone 550 mg TID 550 mg TID N=257
Slide 26: Initial Open Label Extension Data Demonstrate Strong and Durable Efficacy over 52 Weeks
Initial Open Label Extension Data Demonstrate Strong and Durable Efficacy with Deupirfenidone 825 mg TID over at Least 52 Weeks Change in Forced Vital Capacity (FVC) Over 52 Weeks -30 mL to -50 mL1 50 Healthy Older Adults 0 Expected natural lung function decline Change in FVC from Baseline (mL) -50
Slide 27: Deupirfenidone Has Demonstrated Potential for Best-in-class Efficacy
Deupirfenidone Has Demonstrated Potential for Best-in-class Efficacy FVC Relative Benefit Over Placebo Indirect comparison. Not based on head-to-head data Deupirfenidone 825 mg (Ph 2b ELEVATE IPF 26 weeks) no background 81% Deupirfenidone 825 mg (Ph 2b ELEVATE IPF OLE 52 weeks*) no background 84% Pi
Slide 28: Lung Function Stabilized in Patients who Switched from Placebo or Pirfenidone
Lung Function Stabilized in Patients who Switched from Placebo or Pirfenidone to Deupirfenidone 825 mg TID Patients completed 26 weeks of placebo or pirfenidone treatment in Part A and then opted to be re-randomized to deupirfenidone for an additional 26 weeks in the open-label extension (Part B) Me
Slide 29: Phase 3 SURPASS-IPF Trial Design
Phase 3 SURPASS-IPF Trial Design 29
Slide 30: Phase 3 Trial will be Head-to-head vs. Pirfenidone
Phase 3 Trial will be Head-to-head vs. Pirfenidone Design Overview Comparator Head-to-head vs. pirfenidone; no background therapy Deupirfenidone 825 mg TID Arms Pirfenidone 801 mg TID Primary Change from baseline in absolute forced vital capacity (FVC) at 52 weeks Endpoint Based on feedback from the
Slide 31: Commercial Opportunity
bad : BURETECH = o GIVING LIFE TO SCIENCE” 31
Slide 32: Deupirfenidone Has the Potential to be Best-in-class in IPF
Deupirfenidone Has the Potential to be Best-in-class in IPF Strong data package as a Why Deupirfenidone? monotherapy; first therapy to show potential lung function normalization in IPF Broad potential to be the new SOC for IPF patients Best-in-class efficacy: first and only IPF treatment to sh
Slide 33: Deupirfenidone Has the Potential to Be Used Across Multiple Patient Segments
Deupirfenidone Has the Potential to Be Used Across Multiple Patient Segments Potential to capture patients currently on SOC (~25%) AND expand to those who never start (~75%) Patients Who Never Start Treatment ~75% Tolerability risks outweigh modest efficacy benefits, discouraging patients from ever
Slide 34: IPF Market Has the Potential for Substantial Growth
IPF Market Has the Potential for Substantial Growth Global IPF Market: • Despite only ~25% of IPF patients ever starting therapy4, >$5B >$10B SOC agents have achieved blockbuster status • Expected market growth in coming years is driven by: >$5B 1) Increased patient uptake & adherence via the develo
Slide 35: Potential to Expand into Other Progressive, Fibrotic Diseases with High Unmet Need
Potential to Expand into Other Progressive, Fibrotic Diseases with High Unmet Need Progressive pulmonary fibrosis (PPF), also termed progressive fibrotic ILD (PF-ILD), is estimated to affect ~675,000 patients in the US and EU5 CURRENT ADDRESSABLE MARKET: PPF: FUTURE ADDRESSABLE MARKET: US AND EU5 >2
Slide 36: Appendix
bad : BURETECH = o GIVING LIFE TO SCIENCE”
Slide 37: Deupirfenidone is Differentiated from Other IPF Programs
Deupirfenidone is Differentiated from Other IPF Programs Observations From IPF Trial Failures Deupirfenidone Differentiation Idiopathic Nature of Evaluating a new mechanism of action for an Deupirfenidone builds on >10 years of established Disease idiopathic disease is inherently risky human efficac